
Livanova (LIVN) Stock Forecast & Price Target
Livanova (LIVN) Analyst Ratings
Bulls say
LivaNova has demonstrated significant sales growth, with reported sales of $803 million in 2024, reflecting a 29% increase, and management anticipates continued growth, projecting revenues of $940-955 million for the upcoming period. Within the neuromodulation segment, there are optimistic projections regarding the aura6000 device, with estimates of market share expanding from 9.0% in 2027 to 14.9% by 2029, potentially leading to sales of $280 million. The company's diversified revenue streams—approximately 50% from the US, 21% from Europe, and the rest from global markets—enhance its financial stability and growth prospects within the specialized medical device sector.
Bears say
LivaNova is facing potential revenue growth that may stagnate in the low-single digits due to persistent challenges in its Neuromodulation and Cardiovascular sectors, accompanied by operating margin contraction and earnings that are likely to fall below market expectations. Risks also loom regarding the potential failure to secure FDA approval for critical products such as the aura6000, which could exacerbate slower growth trends in both the Neuromodulation and Cardiopulmonary segments. Consequently, these factors collectively contribute to a bearish outlook for the company's financial performance and future prospects.
This aggregate rating is based on analysts' research of Livanova and is not a guaranteed prediction by Public.com or investment advice.
Livanova (LIVN) Analyst Forecast & Price Prediction
Start investing in Livanova (LIVN)
Order type
Buy in
Order amount
Est. shares
0 shares